Kare Chemical Technologies Inc. is a Mississauga-based pharmaceutical technology company developing a scalable catalytic platform for the synthesis of CB1 and CB2 ligands.
Founded by experts in catalysis and pharmaceutical chemistry, Kare is built on a simple idea. Modern therapeutics should not rely on agriculture, biological extraction, or unstable supply chains.
Instead, we convert limonene, a sustainable by-product of citrus processing, into high-purity receptor ligands using a patented catalytic process designed for pharmaceutical development.
Kare is advancing a portfolio of non-psychoactive therapeutic candidates targeting:
By selectively modulating CB1 and CB2 receptor pathways, our compounds aim to deliver therapeutic benefit while minimizing central nervous system side effects.
Our long-term objective is to develop safer alternatives to opioids and next-generation metabolic therapies.
Kare has developed a proprietary catalytic process that converts limonene, a sustainable by-product of the citrus industry, into CB1 and CB2 receptor ligands.
Today, Kare operates from a purpose-built facility in Ontario, Canada, equipped for advanced chemical synthesis and preclinical development.
At the core of Kare is a patented catalytic conversion process that transforms limonene into a stable molecular precursor.
From this precursor, we synthesize a diverse library of CB1 and CB2 ligands and structural analogues.
Kare’s technology has been licensed to pharmaceutical partners and industrialized at scale.
Our platform has supported:
By leveraging green catalytic chemistry and solvent recovery systems, Kare reduces environmental impact while increasing pharmaceutical efficiency.
We believe the next generation of therapeutics must be both scientifically rigorous and environmentally responsible.
Kare holds 45 patent applications across 17 countries and jurisdiction.
Our IP portfolio covers:
This foundation provides freedom to operate globally and supports our evolution into a primary drug development company.
